Mannose-binding lectin deficiency and disease severity in non-cystic fibrosis bronchiectasis: a prospective study

James D. Chalmers; Brian J. McHugh; Catherine Doherty; Maeve P. Smith; John R. Govan; David C. Kilpatrick; Adam T. Hill

doi:10.1016/S2213-2600(13)70001-8

Mannose-binding lectin deficiency and disease severity in non-cystic fibrosis bronchiectasis: a prospective study

James D. Chalmers (Lead / Corresponding author), Brian J. McHugh, Catherine Doherty, Maeve P. Smith, John R. Govan, David C. Kilpatrick, Adam T. Hill

Research output: Contribution to journal › Article › peer-review

77 Citations (Scopus)

Abstract

Mannose-binding lectin (MBL) is a key component of innate immunity. MBL deficiency is common (10-30% of the general population depending on the definition used) and has been associated with disease progression in cystic fibrosis. We aimed to assess the effect of MBL deficiency on disease severity in non-cystic fibrosis bronchiectasis.

Original language	English
Pages (from-to)	224-232
Number of pages	9
Journal	The Lancet Respiratory Medicine
Volume	1
Issue number	3
DOIs	https://doi.org/10.1016/S2213-2600(13)70001-8
Publication status	Published - May 2013

Access to Document

10.1016/S2213-2600(13)70001-8

Mannose Binding Lectin Deficiency, Bacterial Infection and Disease Severity in Chronic Obstructive Pulmonary Disease: Towards Personalised Medicine for COPD
Chalmers, J. (Investigator), Marshall, S. (Investigator), Palmer, C. (Investigator) & Schembri, S. (Investigator)
1/07/13 → 30/06/15
Project: Research

Cite this

@article{6015fb40691b4ba2b8c88d7a553d2c32,

title = "Mannose-binding lectin deficiency and disease severity in non-cystic fibrosis bronchiectasis: a prospective study",

abstract = "Mannose-binding lectin (MBL) is a key component of innate immunity. MBL deficiency is common (10-30% of the general population depending on the definition used) and has been associated with disease progression in cystic fibrosis. We aimed to assess the effect of MBL deficiency on disease severity in non-cystic fibrosis bronchiectasis.",

author = "Chalmers, {James D.} and McHugh, {Brian J.} and Catherine Doherty and Smith, {Maeve P.} and Govan, {John R.} and Kilpatrick, {David C.} and Hill, {Adam T.}",

year = "2013",

month = may,

doi = "10.1016/S2213-2600(13)70001-8",

language = "English",

volume = "1",

pages = "224--232",

journal = "The Lancet Respiratory Medicine",

issn = "2213-2600",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - Mannose-binding lectin deficiency and disease severity in non-cystic fibrosis bronchiectasis

T2 - a prospective study

AU - Chalmers, James D.

AU - McHugh, Brian J.

AU - Doherty, Catherine

AU - Smith, Maeve P.

AU - Govan, John R.

AU - Kilpatrick, David C.

AU - Hill, Adam T.

PY - 2013/5

Y1 - 2013/5

N2 - Mannose-binding lectin (MBL) is a key component of innate immunity. MBL deficiency is common (10-30% of the general population depending on the definition used) and has been associated with disease progression in cystic fibrosis. We aimed to assess the effect of MBL deficiency on disease severity in non-cystic fibrosis bronchiectasis.

AB - Mannose-binding lectin (MBL) is a key component of innate immunity. MBL deficiency is common (10-30% of the general population depending on the definition used) and has been associated with disease progression in cystic fibrosis. We aimed to assess the effect of MBL deficiency on disease severity in non-cystic fibrosis bronchiectasis.

U2 - 10.1016/S2213-2600(13)70001-8

DO - 10.1016/S2213-2600(13)70001-8

M3 - Article

C2 - 24429128

SN - 2213-2600

VL - 1

SP - 224

EP - 232

JO - The Lancet Respiratory Medicine

JF - The Lancet Respiratory Medicine

IS - 3

ER -

Mannose-binding lectin deficiency and disease severity in non-cystic fibrosis bronchiectasis: a prospective study

Abstract

Access to Document

Fingerprint

Projects

Mannose Binding Lectin Deficiency, Bacterial Infection and Disease Severity in Chronic Obstructive Pulmonary Disease: Towards Personalised Medicine for COPD

Cite this